Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

CASE:RMDA Stock Report

Market Cap: ج.م3.2b

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Valuation

Is RMDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RMDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RMDA (EGP2.15) is trading above our estimate of fair value (EGP1.77)

Significantly Below Fair Value: RMDA is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RMDA?

Other financial metrics that can be useful for relative valuation.

RMDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA7.8x
PEG Ratio0.5x

Price to Earnings Ratio vs Peers

How does RMDA's PE Ratio compare to its peers?

The above table shows the PE ratio for RMDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.6x
BIOC GlaxoSmithKlineE
64.3xn/aج.م2.4b
PHAR Egyptian International Pharmaceutical Industries
6.8x14.2%ج.م5.6b
OCPH October PharmaE
8xn/aج.م1.2b
AXPH Alexandria For Pharmaceuticals & Chemical Industries
7.4xn/aج.م1.1b
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E
15x28.8%ج.م3.2b

Price-To-Earnings vs Peers: RMDA is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (21.6x).


Price to Earnings Ratio vs Industry

How does RMDA's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: RMDA is good value based on its Price-To-Earnings Ratio (15x) compared to the Global Pharmaceuticals industry average (24.5x).


Price to Earnings Ratio vs Fair Ratio

What is RMDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RMDA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15x
Fair PE Ratio10.6x

Price-To-Earnings vs Fair Ratio: RMDA is expensive based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (10.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RMDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentج.م2.15
ج.م4.38
+103.6%
19.3%ج.م5.70ج.م3.42n/a5
May ’25ج.م2.06
ج.م4.00
+94.1%
28.7%ج.م5.70ج.م2.10n/a6
Apr ’25ج.م2.70
ج.م3.81
+41.2%
34.2%ج.م5.70ج.م2.10n/a6
Mar ’25ج.م2.90
ج.م3.62
+24.7%
37.4%ج.م5.70ج.م2.10n/a6
Feb ’25ج.م2.01
ج.م2.41
+19.7%
17.9%ج.م3.00ج.م1.84n/a5
Jan ’25ج.م1.65
ج.م2.38
+44.0%
18.6%ج.م3.00ج.م1.84n/a5
Dec ’24ج.م1.67
ج.م2.33
+39.2%
20.5%ج.م3.00ج.م1.84n/a5
Nov ’24ج.م1.52
ج.م2.26
+48.5%
18.4%ج.م2.96ج.م1.84n/a5
Oct ’24ج.م1.41
ج.م2.33
+64.5%
17.7%ج.م2.96ج.م1.84n/a5
Sep ’24ج.م1.39
ج.م2.34
+67.9%
17.0%ج.م2.96ج.م1.90n/a5
Aug ’24ج.م1.43
ج.م2.34
+64.1%
17.0%ج.م2.96ج.م1.90n/a5
Jul ’24ج.م1.56
ج.م2.35
+50.3%
16.5%ج.م2.96ج.م1.90n/a5
Jun ’24ج.م1.53
ج.م2.35
+53.5%
16.5%ج.م2.96ج.م1.90n/a5
May ’24ج.م1.46
ج.م2.26
+54.4%
10.8%ج.م2.50ج.م1.96ج.م2.065
Apr ’24ج.م1.30
ج.م2.26
+73.9%
10.8%ج.م2.50ج.م1.96ج.م2.705
Mar ’24ج.م1.55
ج.م2.15
+39.0%
11.8%ج.م2.46ج.م1.81ج.م2.905
Feb ’24ج.م1.75
ج.م2.18
+24.3%
13.1%ج.م2.56ج.م1.81ج.م2.015
Jan ’24ج.م1.95
ج.م2.18
+11.8%
13.1%ج.م2.56ج.م1.81ج.م1.655
Dec ’23ج.م1.93
ج.م2.18
+12.9%
13.1%ج.م2.56ج.م1.81ج.م1.675
Nov ’23ج.م1.75
ج.م2.02
+15.4%
13.8%ج.م2.56ج.م1.81ج.م1.525
Oct ’23ج.م1.77
ج.م2.02
+13.7%
13.8%ج.م2.56ج.م1.81ج.م1.415
Sep ’23ج.م1.88
ج.م2.04
+8.7%
13.0%ج.م2.56ج.م1.81ج.م1.395
Aug ’23ج.م1.58
ج.م2.04
+29.0%
13.0%ج.م2.56ج.م1.81ج.م1.435
Jul ’23ج.م1.44
ج.م2.04
+42.0%
13.0%ج.م2.56ج.م1.81ج.م1.565
Jun ’23ج.م1.38
ج.م2.04
+48.1%
13.0%ج.م2.56ج.م1.81ج.م1.535
May ’23ج.م1.46
ج.م2.12
+44.8%
12.8%ج.م2.56ج.م1.81ج.م1.465

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.